Background
Methods
Study populations
ANXA1 staining
Statistical analyses
Results
BCAC patients | BRCA1|2 mutation carriers | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
ANXA1 negative | ANXA1 positive | ANXA1 negative | ANXA1 positive | ||||||||
n | % | n | % | P valuea | n | % | n | % | P valueb | P valuec | |
5,040 | 87.6 | 712 | 12.4 | 55 | 51.4 | 52 | 48.6 | <0.0001 | |||
Age of diagnosis | <0.0001 | 0.2253 | 0.0401 | ||||||||
<50 years old | 2,462 | 85.6 | 413 | 14.4 | 34 | 47.2 | 38 | 52.8 | |||
≥50 years old | 2,578 | 89.6 | 299 | 10.4 | 21 | 60.0 | 14 | 40.0 | |||
Missing | 0 | 0 | 0 | 0 | |||||||
BRCA status | 0.0026 | 0.0583 | |||||||||
Non-carrier | 858 | 83.6 | 168 | 16.4 | |||||||
BRCA1 | 11 | 61.1 | 7 | 38.9 | 25 | 42.4 | 34 | 57.6 | |||
BRCA2 | 14 | 73.7 | 5 | 26.3 | 30 | 62.5 | 18 | 37.5 | |||
Missing | 3,812 | 430 | 0 | 0 | |||||||
Menopausal status | 0.0330 | ||||||||||
Pre- | 1,556 | 86.2 | 250 | 13.8 | |||||||
Post- | 2,258 | 88.3 | 298 | 11.7 | |||||||
Missing | 1,226 | 164 | |||||||||
Morphology | <0.0001 | 0.5946 | 0.0235 | ||||||||
Ductal | 3,558 | 86.2 | 568 | 13.8 | 33 | 50.8 | 32 | 49.2 | |||
Lobular | 710 | 94.3 | 43 | 5.7 | 11 | 61.1 | 7 | 38.9 | |||
Missing | 772 | 101 | 11 | 13 | |||||||
Grade | <0.0001 | 0.0040 | 0.1460 | ||||||||
1 | 1,129 | 95.0 | 59 | 5.0 | 7 | 77.8 | 2 | 22.2 | |||
2 | 2,246 | 92.8 | 173 | 7.2 | 26 | 66.7 | 13 | 33.3 | |||
3 | 1,306 | 75.2 | 431 | 24.8 | 19 | 35.8 | 34 | 64.2 | |||
Missing | 359 | 49 | 3 | 3 | |||||||
Tumor size | <0.0001 | 0.9910 | 0.7780 | ||||||||
≤2 cm | 2,809 | 88.8 | 354 | 11.2 | 31 | 51.7 | 29 | 48.3 | |||
>2 cm and ≤5 cm | 1,610 | 86.5 | 252 | 13.5 | 19 | 52.8 | 17 | 47.2 | |||
>5 cm | 109 | 79.9 | 29 | 21.0 | 2 | 50.0 | 2 | 50 | |||
Missing | 512 | 77 | 3 | 4 | |||||||
Node status | 0.2725 | ||||||||||
Negative | 2,669 | 87.1 | 395 | 12.9 | 31 | 47.0 | 35 | 53.0 | 0.3044 | 0.1790 | |
Positive | 1,955 | 88.1 | 263 | 11.9 | 22 | 59.5 | 15 | 40.5 | |||
Missing | 416 | 54 | 2 | 2 | |||||||
ER status | <0.0001 | ||||||||||
Negative | 977 | 67.8 | 465 | 32.2 | 13 | 28.3 | 33 | 71.7 | <0.0001 | 0.7373 | |
Positive | 3,796 | 95.0 | 200 | 5.0 | 36 | 75.0 | 12 | 25.0 | |||
Missing | 267 | 47 | 6 | 7 | |||||||
PR status | <0.0001 | ||||||||||
Negative | 1,435 | 75.9 | 455 | 24.1 | 20 | 35.1 | 37 | 64.9 | <0.0001 | 0.1670 | |
Positive | 3,159 | 94.8 | 175 | 5.2 | 27 | 77.1 | 8 | 22.9 | |||
Missing | 446 | 82 | 8 | 7 | |||||||
HER2 status | 0.1328 | ||||||||||
Negative | 3,484 | 88.7 | 442 | 11.3 | 25 | 48.1 | 27 | 51.9 | 1.0000 | 0.0684 | |
Positive | 643 | 86.8 | 98 | 13.2 | 1 | 50.0 | 1 | 50.0 | |||
Missing | 913 | 172 | 29 | 24 | |||||||
EGFR-CK5/6 statusd | <0.0001 | ||||||||||
Negative | 3,317 | 93.8 | 218 | 6.2 | |||||||
Positive | 541 | 67.6 | 259 | 32.4 | |||||||
Missing | 1,182 | 235 | |||||||||
p53 statuse | 0.0572 | ||||||||||
Negative | 172 | 90.1 | 19 | 9.9 | 17 | 45.9 | 20 | 54.1 | 0.0211 | 0.8116 | |
Positive | 57 | 80.3 | 14 | 19.7 | 3 | 14.3 | 18 | 85.7 | |||
Missing | 596 | 89 | 35 | 14 | |||||||
Adjuvant chemotherapy | <0.0001 | ||||||||||
No | 2,593 | 89.9 | 282 | 10.1 | |||||||
Yes | 1,585 | 83.2 | 320 | 16.8 | |||||||
Missing | 862 | 100 | |||||||||
Adjuvant hormonal therapy | <0.0001 | ||||||||||
No | 2,059 | 82.5 | 438 | 17.5 | |||||||
Yes | 2,562 | 92.6 | 204 | 7.4 | |||||||
Missing | 419 | 70 |